OrbiMed Advisors LLC, together with OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC, filed a Form 4 on November 10, 2026, disclosing purchases of Electra Therapeutics, Inc. (NASDAQ:ETRA) common stock across three trading days from November 6 through November 10, 2026.

Key Highlights

  • Six purchase transactions in ETRA common stock were reported across November 6, 9, and 10, 2026, all coded as open-market purchases (Code P).
  • Total shares acquired: 92,116 shares across both OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P.
  • Purchase prices ranged from $7.85 per share on November 6, to $8.24 on November 9, to $8.45 on November 10, 2026.
  • Post-transaction beneficial ownership: OPI VII position stands at 5,255,278 shares; OrbiMed Genesis position stands at 2,194,579 shares, both held indirectly.
  • Three reporting persons filed jointly: OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC, each located at 601 Lexington Avenue, 54th Floor, New York, NY 10022.
  • Carl L. Gordon serves as the designated board representative of OrbiMed Advisors on Electra Therapeutics' board of directors, according to the filing.

OrbiMed's Multi-Day Purchases in Electra Therapeutics Common Stock

According to the filing, OrbiMed Advisors LLC is the managing member of both OrbiMed Capital GP VII LLC, the general partner of OrbiMed Private Investments VII, LP ("OPI VII"), and OrbiMed Genesis GP LLC, the general partner of OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). By virtue of these relationships, OrbiMed Advisors and the respective general partners may be deemed to have voting and investment power over the securities held by each fund.

The filing reports that on November 6, 2026, OPI VII acquired 9,816 shares at $7.85, bringing its holdings to 5,230,578 shares, while OrbiMed Genesis acquired 39,600 shares at $7.85, bringing its holdings to 2,176,579 shares. On November 9, OPI VII purchased 4,000 shares at $8.24 (holdings: 5,234,578) and OrbiMed Genesis purchased 16,000 shares at $8.24 (holdings: 2,192,579). On November 10, OPI VII purchased 20,700 shares at $8.45 (holdings: 5,255,278) and OrbiMed Genesis purchased 2,000 shares at $8.45 (holdings: 2,194,579). All transactions are reported as indirectly owned.

The filing states that OrbiMed Advisors "exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership" of the shares held by OPI VII and OrbiMed Genesis. The filing further notes that each reporting person "disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended, except to the extent of its pecuniary interest therein, if any."

What Was Disclosed

Three affiliated OrbiMed entities jointly reported six open-market purchases of Electra Therapeutics common stock between November 6 and November 10, 2026, totaling 92,116 shares acquired at prices between $7.85 and $8.45 per share, all held indirectly through two investment funds.